News & Updates
Showing Multidisciplinary articles
Showing
Resveratrol supplements confer minimal benefits in T2D, MetS, NAFLD
Supplementation with resveratrol does not appear to provide much benefit in the management of cardiometabolic risk factors in patients with type 2 diabetes (T2D), metabolic syndrome (MetS), and nonalcoholic fatty liver disease (NAFLD), suggests a study.
Resveratrol supplements confer minimal benefits in T2D, MetS, NAFLD
18 Nov 2021
Subgroup findings boost dupilumab benefit for CRSwNP, comorbid asthma
In post hoc analyses of the phase III SINUS-24 and SINUS-52 trials, the monoclonal antibody dupilumab continued to render improvements for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP), as well as among those with comorbid asthma regardless of asthma characteristics.
Subgroup findings boost dupilumab benefit for CRSwNP, comorbid asthma
18 Nov 2021
Dapagliflozin in COVID-19: Outcomes consistent regardless of kidney status
Secondary analysis of the DARE-19* trial presented at ASN Kidney Week 2021 has shown that the effect of dapagliflozin in patients with cardiometabolic risk factors hospitalized with COVID-19 is consistent regardless of kidney disease status.
Dapagliflozin in COVID-19: Outcomes consistent regardless of kidney status
17 Nov 2021
Bleeding common after acute coronary syndrome
Acute coronary syndrome often leads to bleeding events, particularly at gastrointestinal sites, a recent study has found. Such complications are more likely to occur among older patients and those with hypertension, heart failure, and low baseline haemoglobin levels.